Journal of Clinical and Preventive Cardiology

REVIEW ARTICLE
Year
: 2018  |  Volume : 7  |  Issue : 4  |  Page : 148--153

Soluble ST2: A biomarker to monitor heart failure progression and treatment


Marin Nishimura1, Justin Sharim2, Yu Horiuchi3, Olga Barnett4, Nicholas Wettersten1, Alan S Maisel1 
1 Division of Cardiovascular Medicine, University of California San Diego, San Diego, California, USA
2 Department of Medicine, University of California, San Diego, California, USA
3 Division of Cardiovascular Medicine, Veterans Affairs Medical Center, San Diego, California, USA
4 Department of Cardiology, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Correspondence Address:
Dr. Marin Nishimura
9500 Gilman Dr Mc 7411C La Jolla, California 92093-7411
USA

Measurement of cardiac biomarkers has become routine for the care of patients with heart failure (HF). While troponin and natriuretic peptides are well-entrenched in the guidelines, soluble ST2 (sST2) is a novel biomarker that has shown consistent performance and is ready for clinical use. Multiple studies support the use of sST2 in both acute and chronic HF for prognostication. We suggest a novel scheme to guide HF management based on ambulatory sST2 levels.


How to cite this article:
Nishimura M, Sharim J, Horiuchi Y, Barnett O, Wettersten N, Maisel AS. Soluble ST2: A biomarker to monitor heart failure progression and treatment.J Clin Prev Cardiol 2018;7:148-153


How to cite this URL:
Nishimura M, Sharim J, Horiuchi Y, Barnett O, Wettersten N, Maisel AS. Soluble ST2: A biomarker to monitor heart failure progression and treatment. J Clin Prev Cardiol [serial online] 2018 [cited 2022 Dec 7 ];7:148-153
Available from: https://www.jcpconline.org/article.asp?issn=2250-3528;year=2018;volume=7;issue=4;spage=148;epage=153;aulast=Nishimura;type=0